SANUWAVE Health  (SNWV-OTC)

SNWV: Disappointing Q3 Revenue But SNWV Expects Record Sales in 2018

With the updates to our model, we have SNWV generating approximately $10M (when including JV revenue – which on GAAP basis will be accounted for as a component in equity interest calculation) in revenue in 2019 - based on the SNN comp 2019 P/S multiple, this values SNWV at about $0.25/share.

Current Price (11/28/17) $0.15
Valuation $0.25

OUTLOOK

The relative dud of a topline number in Q3, coupled with longer than anticipated runway in generating initial sales from new territories and lack of any obvious meaningful revival in sales from S. Korea, means revenue will almost certainly be nowhere close to a record in 2017. But, based on SNWV’s comments on the Q3 call relating to anticipated demand (which includes recent feedback from distributors), they do expect to see record revenue in 2018 (regardless of FDA’s decision). Relative to the operational update – in terms of the OUS business, management noted on the call that they have recently been and will continue to be busy attending industry events and, even holding their own symposium, with the goal of generating additional awareness of their device with the hope that it translates into a greater ramp in international sales. Clinical data and KOL attention may be key to sparking additional demand and both of these are main topics of SNWV’s refreshed strategy. Material contribution from MundiMed could also come in 2018.

As it relates to the U.S. strategy, it is a wait-and-see period with the hope that FDA returns a positive decision to the De Novo application, which has now been outstanding for 493 days.
Q3 Results, Operational Update: Another Top-Line Dud But We Still Expect OUS Adoption To Improve....

SANUWAVE reported Q3 financial results and provided a business update. Similar to the first two quarters of the year, revenue was disappointing. But, given that management had mentioned on the Q2 call (in August) that July was a record in terms of device shipments and that they were expecting Q3 sales to be up dramatically from the prior quarter, the most recent number was particularly disheartening. The relative du of a topline number in Q3, coupled with longer than anticipated runway in generating initial sales from new territories and lack of any obvious meaningful revival in sales from S. Korea (i.e. SNWV's leading market), means revenue will almost certainly be nowhere close to a record in 2017. But, while management's 2017 revenue prediction will not be met, based on their comments on the Q3 call relating to anticipated demand (which includes recent feedback from distributors), they do expect to see record revenue in 2018 (regardless of FDA's decision).

The good news as it relates to recent financials is that operating expenses trended much lower from Q2 and, despite the miss to management's sales guidance, cash burn remained on the low end of SNWV's range of expectations.

Relative to the operational update – in terms of the OUS business, management noted on the call that they have recently been and will continue to be busy attending industry events and, even holding their own symposium, with the goal of generating additional awareness of their device with the hope that it translates into a greater ramp in international sales. Clinical data and KOL attention may be key to sparking additional demand and both of these are main topics of SNWV's refreshed strategy. The recently penned Mundimed agreement will not result in significant income in 2017 (although initial upfront payment to SNWV and a handful of device sales to Mundimed should be incremental to Q4) but, assuming consummation of the definitive agreement, approval of dermaPACE by Brazilian regulators and launch shortly thereafter, it is possible that material contribution from the JV could happen in 2018.

As it relates to the U.S. strategy, while SNWV indicated that they have been in regular contact with FDA, their last official interaction was during the summer when they submitted formal responses to additional questions from the agency. Indications are that this is now a wait-and-see period with the hope that FDA returns a positive decision to the De Novo application soon.

Financials
Q3 revenue was $162k, representing yoy decline of 37%. While revenue grew 46% sequential, the qoq comparable was relatively extremely easy given that Q2's sales of just $111k were the lowest since at least Q2 2008 (which is the furthest back that we looked). Revenue was $422k through the first nine months of 2017 – which is down 42% from the comparable prior-year period and represents the lowest revenue among any consecutive three-quarter period since the $382k generated from Q4 '09 to Q2 '10.

Q3 revenue missed our $371k estimate by 56%, which follows a 55% miss in Q2 ($111k A vs. $244k E) and a 19% miss in Q1 ($150k A vs. $185k E). Based on SNWV's comments on recent earnings calls, we had opined that revenue weakness may have been related to mostly non-fundamental reasons such as adverse timing or, in the case of S. Korea, political turmoil. But, given continued trends of estimates (ours and management's) overshooting actuals by large margins with seemingly little relationship between the misses and the presumed causes, we now believe demand-related traction via expansion of the distribution footprint may not materialize as quickly as we had previously anticipated.

S. Korea, which SNWV has indicated remains the company's leading market, was expected to represent much of the anticipated revenue growth during 2017 as a result of availability of reimbursement. That appears to not have materialized – whether that is due to the political upheaval earlier this year or something else, is not completely clear. But, the fact that SNWV's distributor accounts for 78% of the company's A/R balance and 48% of their bad debt balance, may suggest that their S. Korean partner is having difficulty finding buyers.

While we have tempered our forecasted sales from S. Korea, for several reasons we do think that it is more likely than not that revenue growth will materialize from this territory. Management provided some specifics on the Q3 call relative to utilization in S. Korea – noting the number of reimbursement cycles that clinicians have gone through – and while the figures (i.e. 300 to 400 reimbursement cycles) are not particularly meaningful to us (i.e. we don't have the decoder ring), the fact that SNWV can track activity and indicated that it is increasing is a positive development, in our opinion. Management also noted on the Q3 call that the order book for 2018 is "dramatically larger than we've ever seen out of any one country". Additionally, SNWV mentioned that new clinical and published
data should be forthcoming from S. Korea in both DFU as well as scar tissue (following C-section) – our experience is that positive and compelling published data is typically the single-most influential aspect of any sales/marketing strategy.

Another issue that management pointed towards that has hampered demand growth is longer-than-anticipated regulatory approval in many of the territories where SNWV recently signed distribution contracts. While SANUWAVE brought on distribution in six new territories during 2017, regulatory approval is still outstanding in many of these. We think another factor may be slower than anticipated adoption of SNWV’s device in countries where it has recently gained regulatory clearance. KOL-support and leading with clinical data is now at the forefront of marketing strategies, which may improve uptake.

Q3 OpEx was $742k, which is well below our $909k estimate and a significant decrease from both Q2 2017 ($1.39M) and Q3 2016 ($912k). The majority of the sequential decline reflects lower non-cash stock compensation in Q3.

Cash used in operating activities was $372k and $945k ($819k and $2.42M, ex-changes in working capital) in the three and nine months ending 9/30/2017. Cash balance was just $40k at Q3 quarter-end. Per the 10-Q, SNWV issued $1.12M in 10% convertible notes in early November. Management continues to expect monthly cash burn to average $125k - $225k through the remainder of 2017. While the upfront (received in Q4) and subsequent (over the first 18 months) fee payments from MundiMed should provide incremental capital, it will not be enough to fully fund operations. SNWV indicated that they have been evaluating similar agreements with potential partners in India, China and the Middle East which, if closed, could also possibly bring in additional funds to the company. But, we continue to expect the company to look to raise additional cash via the sale of equity or debt or potentially through one or more partnering arrangements.

International Strategy...

As a reminder, earlier this year management outlined several goals that they expected to accomplish by year-end including the onboarding of an additional 7 - 10 new distributors/territories. Including the MundiMed JV, they are now at number six and based on comments on the Q3 call, management believes that they will further expand their international footprint by the end of 2017. While many of the recent additions are in the orthopedics space, MundiMed adds a high-potential wound care channel and other DFU opportunities could follow - which could be facilitated if and when dermaPACE is approved in the U.S. (as OUS uptake is likely to benefit from implied validation that comes from FDA approval). SNWV is also currently evaluating several wound care related distributors in parts of Europe.

Recent “wins” on this front included the signing of major distributors in Taiwan and Indonesia as well as engaging an organization in Columbia to source qualified distributors in that country. Romania is another country where they also recently added distribution. SNWV is also active in looking to expand to other parts of Asia (including China, India and Thailand) as well as to the Middle East and S. Africa – all of which represent relatively large populations and could be particularly well-suited for a MundiMed-type arrangement (i.e. JV with large, local and experienced distributor). SNWV attended both MEDICA and Wounds Canada and mentioned that feedback from distributors suggests device sales should significantly pick up next year and result in record international sales. However, given the optimistic-yet-not-fulfilled assumptions during 2017 related to revenue, our model implies somewhat more conservative OUS (ex-MundiMed) sales (although we do expect significant growth compared to 2017, we are modeling 2018 int'l sales slightly below that of 2016).

SNWV recently updated their strategy in selecting distribution partners with additional emphasis placed on expertise in wound care versus orthopedics given the differences and difficulties in detailing to two distinct end-markets. Management also noted that some of their distributors - notably Alat Medika (a prominent Indonesian med-tech company) - also have the capabilities to help facilitate clinical trial activities in their respective territories.

As we have noted in the past, given the dearth of non-invasive and relatively inexpensive DFU-treatment options, we think dermaPACE has a place in chronic wound care and believe a reasonable scenario exists where SNWV can reach a point of operating profitability from OUS business alone. Clearly, much of the ultimate success of the international strategy may rely on partnering with organizations with sufficient and appropriate expertise, contacts and channel depth (at both private and national healthcare levels) to execute their strategy. We have yet to see much substance (in the form of revenue) from this international expansion - although given the lag between fundamental operational progress and related revenue, the next few quarters should be a much better judge in that regard.
This international strategy involves targeting key opinion leaders to help drive adoption. Management noted that it typically takes about 3 – 9 months after a new distributor/territory comes online to be able to assess the potential of the launch and before any significant related revenue may be generated. As such, assuming SNWV continues to expand their distribution footprint through the remainder of the current year, much of the revenue benefit may not be realized until 2018. Nonetheless, we had expected to see a more meaningful contribution from new territories by now, particularly as new distributors are required to purchase at least two systems initially ($40k - $60k revenue).

As noted, management mentioned on the Q2 call (mid-August) that they had record shipments in the month of July and that they continued to expect 2017 would be a record year in terms of revenue. While our model was much more conservative (and did not imply record sales for 2017), clearly even our assumptions were too optimistic. The speed with which dermaPACE gains regulatory approval in new territories appears to have been overestimated, as does the rate of adoption in those countries where the device is already cleared for sale.

While it is not completely clear what the issues have been, we have found that it is not uncommon to overestimate initial adoption. We have seen adoption of novel therapies (particularly therapeutic devices) hampered by a variety of headwinds including lack of appropriate reimbursement, "insufficient" clinical evidence, healthcare system structural impediments, less-than-competent distribution, less-than-compelling competitive differentiation, unworkable economics, cost and lack of access to healthcare, among a whole host of others.

But, as noted, the recent feedback from SNWV’s distribution partners appears to be favorable as it relates to anticipated demand. As these local distributors should have the best insight into what challenges they may face in their respective markets, presumably their optimism suggests that any hurdles are manageable and demand will be relatively robust in 2018. Publication of additional clinical trial manuscripts as well as a determined focus at the KOL level, will be strategies that SNWV will employ to improve adoption. Supplemental awareness-building efforts, including attendance and participation at industry events and conferences, such as MEDICA, as well as hosting their (first in a long time) own symposium (which management mentioned is expected to be well-attended) will also be a part of the adoption-sparking strategy game plan.

In Parallel...
In parallel to broadening their geographic footprint SNWV will also look to expand the indicated uses for their device. While SNWV’s tight cash constraints have meant that certain clinical validation studies have moved slower than previously anticipated, further progress is expected. Specific studies that SNWV has cited over the recent past and which could aid in marketing efforts include:

- **Belgium DFU Home Care study:** SNWV has partnered with Ortho-Medico, their distribution partner for the Benelux region, in sponsoring a clinical trial evaluating dermaPACE in the treatment of diabetic foot ulcers in the home-care setting. The trial is being conducted by the Free University of Brussels and UZ Brussel (University Hospital) and is expected to include ~100 DFU patients randomized to either dermaPACE or standard-of-care. As all patients will be treated in-home (i.e. outside the clinic/hospital), results of the study are expected to help broaden the potential international customer base to users such as home-health professionals and organizations. As DFU patients often have significant mobility limitations and challenges, trips to the hospital for treatment can present substantial hardship. As such, we think home-health could be a particularly attractive segment for dermaPACE and one that results of this study, assuming positive, could help SNWV to exploit.

- **Australian Venous Leg Ulcer studies:** SNWV’s Australian distributor, in collaboration with researchers in Melbourne, has participated in several case studies using dermaPACE in venous leg ulcers. Case study included seven patients - management noted on the Q2 2017 that this study has now completed.

- **S. Korea**: several devices placed at leading universities in S. Korea with the goal of facilitating clinical evidence of effectiveness of treating DFUs. SNWV also recently noted that some KOLs in S. Korea have also used dermaPACE for other applications including for scar reduction following C-section.

- **U.S. studies**: In addition to DFU, SNWV is investigating the use of their technology in the healing of post-operative scars and in improving vascularization – both of which lend themselves to dermaPACE’s method of action – that is promotion of blood flow and related healing. While these studies are still in the early planning stages, management did offer some general information on the Q4 2016 call - including that the post-op scarring program may initially involve patients undergoing elective cosmetic surgery (such as tummy-tucks) with each patient representing both treatment and control arms (e.g. one incision scar would be treated with dermaPACE, while the other would receive standard-of-care). If deemed successful, larger studies could follow – including potentially overseas.
**FDA Pathway Update...**

While management noted that they will continue to follow their policy of disseminating any material news as it relates to their quest towards FDA clearance of dermaPACE via press releases, they do continue to provide brief updates on the status of their de novo filing with FDA on earnings calls. As a reminder SNWV filed their de novo application on July 23, 2016 requesting that dermaPACE be classified as a Class II device.

In early 2017 SNWV received from FDA additional questions regarding clarifications related to the filing, clinical trial data and “technical performance and labeling.” Management noted on the Q2 call (in August) that they submitted their responses to these questions on July 17th and responded to subsequent questions from the agency during the week-ending August 23rd. Since then SNWV has received regular, yet less formal, inquiries from FDA – management has indicated that they have sufficiently responded to these requests.

Management had previously relayed that MCRA (based on their experience) believed a final response (i.e. yes or no) from FDA will come by current year-end. For reference, a study by Hogan Lovells U.S. LLP found that average review time for De Novo applications in 2014 and 2015 was almost 400 days. As of today's date (11/28/2017), SNWV's application has been outstanding for 493 days.

See our Appendix for refresher on dermaPACE U.S. pivotal studies as well as the de novo filing.

**Model update:**

We are maintaining our assumption that dermaPACE receives FDA clearance in late 2017 and continue to project launch of the device in the U.S. in 1H 2018. And while we think the de novo pathway makes sense based on the reasons we cite, given the ambiguity in terms of FDA's decision-making process along with other unknowns including anything that may be unique to the switch from PMA to de novo, we are maintaining a high (i.e. 70% sales haircut) revenue discount.

We believe that our assumed, yet risk-adjusted, eventual FDA clearance/approval is a reasonable assumption given FDA's continued engagement with SNWV, strong safety profile of dermaPACE, significant efficacy on 100% wound closure in the combined data as well as efficacy in sub-groups (even at 12 weeks), on secondary measures and less invasive nature of dermaPACE compared to other DFU therapies. This is further reinforced by SNWV sufficiently addressing and responding to FDA's questions.

Our 70% haircut represents risk that dermaPACE fails to gain regulatory approval as well as certain operational risks including failure to raise additional capital, slow adoption of dermaPACE upon launch and insufficient sales/marketing capabilities (whether that be in-house or via 3rd party distribution), among others. **Additional positive and tangible headway towards approval as well as mitigation of other operational risks would likely warrant a reduction in this risk discount (and would likely benefit our price target).** We have dermPACE launching in the U.S. in 1H 2018. We model 2019 (the first full year that dermaPACE is in U.S. market) U.S. revenue of $16.5M – which equates to $5M with the risk discount.

We had not previously and still do not incorporate any potential contribution from non-medical applications or expansion of the U.S. label in additional indications including (for example) post-op scarring. This is also subject to updating and is contingent upon further development progress, solidifying proof-of-concept and additional progress towards eventual commercialization – whether organically or via licensing / partnering. It is also possible SNWV looks to just monetize the related IP – which also holds potential promise for revenue, or at least financing upside. To be clear, we think certain of these non-medical applications and expansion of the medical-related label may have real and, potentially significant value and we continue to remain encouraged by the recent development and validation progress – but we still feel it is too early to assign an estimated value – whether on a related-revenue or related-monetization basis.

Our modeled revenue also consists of OUS sales of ortho/dermaPACE. While we think it is reasonable to assume that management's recent efforts to grow ex-U.S. sales via new distribution agreements and entry into new geographically territories can pay additional dividends in the form of a steepening of the overseas revenue curve, we have tempered the assumed rate of increase based on certain recent headwinds. We have OUS sales (not including the MuniMed JV) growing from about $1.4M in 2016 to approximately $2.4M (adjusted down from $3.1M) in 2019.
Our model now also contains forecasted contribution from the MundiMed JV, which incorporates the following assumptions:

- dermaPACE launches in Brazil in early 2019
- per-patient revenue is $725. Calculated as, 25% of estimated ($2,900) primary healing cost per-patient. Comprehensive study by Rezende, et al. calculated per-patient primary healing of DFU in Brazil cost $2,517 in 2008, equal to ~$2,900 today. We assume ~25% of that cost will be reimbursable for dermaPACE treatment.
- Brazil DFU market size equals ~1M people
- 0.5% penetration (of only the DFU market) in the first year (2019) on the market
- 30% gross margin and operating expenses equal to approximately 30% of revenue
- We also include some fee-income as well as some device sales to the JV in 2018 and 2019 (i.e. the out-years in our model)

We have used P/S comp as our valuation methodology – for consistency, we continue to use that. Smith & Nephew has traded at approximately 3.5x analyst's 2019 forecasted revenue. With the updates to our model, we have SNWV generating approximately $10M (when including JV revenue – which on GAAP basis will be accounted for as a component in equity interest calculation) in revenue in 2019 - based on the SNN comp 2019 P/S multiple, this values SNWV at about $0.25/share.
**SANUWAVE Health, Inc.**

<table>
<thead>
<tr>
<th></th>
<th>2015 A</th>
<th>Q1A</th>
<th>Q2A</th>
<th>Q3A</th>
<th>Q4A</th>
<th>2016 A</th>
<th>Q1A</th>
<th>Q2A</th>
<th>Q3A</th>
<th>Q4A</th>
<th>2017 E</th>
<th>2018 E</th>
<th>2019 E</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Revenues</strong></td>
<td>$965.5</td>
<td>$269.3</td>
<td>$203.4</td>
<td>$255.7</td>
<td>$647.7</td>
<td>$1,376.1</td>
<td>$149.6</td>
<td>$111.0</td>
<td>$161.6</td>
<td>$251.8</td>
<td>$584.0</td>
<td>$3,615.0</td>
<td>$7,894.0</td>
</tr>
<tr>
<td><strong>YOY Growth</strong></td>
<td>6.8%</td>
<td>73.8%</td>
<td>57.8%</td>
<td>58.0%</td>
<td>70.5%</td>
<td>42.5%</td>
<td>51.1%</td>
<td>39.7%</td>
<td>42.8%</td>
<td>68.5%</td>
<td>61.2%</td>
<td>67.4%</td>
<td>38.8%</td>
</tr>
<tr>
<td><strong>Cost of Revenues</strong></td>
<td>$285.0</td>
<td>$73.2</td>
<td>$78.0</td>
<td>$98.7</td>
<td>$315.3</td>
<td>$565.1</td>
<td>$551.4</td>
<td>$247.7</td>
<td>$617.0</td>
<td>$141.6</td>
<td>$283.1</td>
<td>$1,002.0</td>
<td>$2,487.3</td>
</tr>
<tr>
<td><strong>Gross Income</strong></td>
<td>$680.5</td>
<td>$196.1</td>
<td>$125.4</td>
<td>$157.0</td>
<td>$332.4</td>
<td>$810.9</td>
<td>$94.4</td>
<td>$86.4</td>
<td>$99.9</td>
<td>$110.2</td>
<td>$300.9</td>
<td>$2,013.0</td>
<td>$5,406.7</td>
</tr>
<tr>
<td><strong>Net Margin</strong></td>
<td>28.5%</td>
<td>73.8%</td>
<td>61.4%</td>
<td>58.9%</td>
<td>58.2%</td>
<td>77.8%</td>
<td>61.7%</td>
<td>78.0%</td>
<td>55.14</td>
<td>78.0%</td>
<td>57.7%</td>
<td>52.6%</td>
<td>58.3%</td>
</tr>
<tr>
<td><strong>Diluted Shares O/S</strong></td>
<td>75,220</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>139,100</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Write down of assets</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Operating Income</strong></td>
<td>($4,437.8)</td>
<td>($690.5)</td>
<td>($1,018.2)</td>
<td>($833.6)</td>
<td>($774.3)</td>
<td>($3,516.5)</td>
<td>($620.6)</td>
<td>($1,309.4)</td>
<td>($647.8)</td>
<td>($884.8)</td>
<td>($3,552.7)</td>
<td>($2,958.8)</td>
<td>($2,883.2)</td>
</tr>
<tr>
<td><strong>Depreciation</strong></td>
<td>$680.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$2,735.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SG&amp;A</strong></td>
<td>$2,735.1</td>
<td>$499.1</td>
<td>$589.9</td>
<td>$645.9</td>
<td>$938.9</td>
<td>$2,673.8</td>
<td>$448.6</td>
<td>$951.9</td>
<td>$475.4</td>
<td>$692.0</td>
<td>$2,567.9</td>
<td>$6,188.9</td>
<td>$75.0</td>
</tr>
<tr>
<td><strong>Write down of assets</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pre-Tax Income</strong></td>
<td>($4,810.2)</td>
<td>($1,724.6)</td>
<td>($1,122.1)</td>
<td>($1,139.8)</td>
<td>($2,451.5)</td>
<td>($6,438.0)</td>
<td>($493.5)</td>
<td>($1,415.9)</td>
<td>($851.3)</td>
<td>($1,119.8)</td>
<td>($3,970.6)</td>
<td>($4,233.8)</td>
<td>($4,183.2)</td>
</tr>
<tr>
<td><strong>Net Income</strong></td>
<td>($4,823.7)</td>
<td>($1,721.6)</td>
<td>($1,127.8)</td>
<td>($1,142.1)</td>
<td>($2,465.5)</td>
<td>($6,456.9)</td>
<td>($493.5)</td>
<td>($1,415.9)</td>
<td>($851.3)</td>
<td>($1,119.8)</td>
<td>($3,970.6)</td>
<td>($4,242.3)</td>
<td>($3,633.4)</td>
</tr>
<tr>
<td><strong>EPS (continuing ops)</strong></td>
<td>($0.08)</td>
<td>($0.02)</td>
<td>($0.01)</td>
<td>($0.01)</td>
<td>($0.02)</td>
<td>($0.00)</td>
<td>($0.00)</td>
<td>($0.00)</td>
<td>($0.00)</td>
<td>($0.00)</td>
<td>($0.00)</td>
<td>($0.00)</td>
<td>($0.00)</td>
</tr>
<tr>
<td><strong>Diluted Shares O/S</strong></td>
<td>65,025</td>
<td>75,220</td>
<td>102,646</td>
<td>115,529</td>
<td>137,084</td>
<td>107,620</td>
<td>139,100</td>
<td>139,100</td>
<td>139,100</td>
<td>139,100</td>
<td>139,100</td>
<td>139,100</td>
<td>139,100</td>
</tr>
</tbody>
</table>

© Copyright 2017, Zacks Investment Research. All Rights Reserved.
APPENDIX

De Novo Refresher

Pursuing De Novo U.S. Regulatory Pathway, Filing Made July 2016, Responded to Questions Jan 2017 ...

On the Q1 '16 call in May 2016 management noted that, following their meeting with FDA, that they were in the process of putting together a PMA filing and at that time were anticipating the submission would be made in June or July. Clearly SNWV decided to consider alternative options and, apparently after additional consultation with MCR, abandoned the PMA route in favor of the de novo pathway. On August 11th 2016 they announced that they submitted a de novo filing to FDA (on July 23rd) requesting that dermaPACE be classified as a Class II device. SNWV had noted previously that they were expecting a response from the agency in Q4 2016 but on the Q3 call (on November 10th) mentioned that they expected to hear back from FDA in January 2017 – also noting that they expected FDA's response would be in the form of additional questions.

On the Q4 ‘16 earnings call in early April 2017 management mentioned that their most recent interaction with the U.S. regulatory agency was in late-January/early-February of this year and consisted of responding to questions and clarifications related to the filing, clinical trial data and “technical performance and labeling.”

So while management did not provide specifics of the questions or other inquiries from FDA, we interpreted their April 2017 message to be that the process continues to move along with no particular surprises. Management did specifically mention that they have been promptly replying to all of FDA's inquiries and that they (i.e. SNWV) expects a final decision from the agency later this year.

Our Comments:

De Novo primer: FDA created the de novo pathway in an effort to help streamline approval of novel, low-to-moderate risk medical devices. Prior to de novo the only route for new devices and for which there was not an acceptable predicate, regardless of their risk profile, was the relatively long, arduous and costly PMA process. In other words, novel, low risk devices were, by default, considered Class III, or high risk, medical devices if a similar device had not already been approved by FDA (i.e. lack of predicate excluded 510(k) route).

The 510(k) de novo pathway was created as part of the FDA Modernization Act of 1997 which was meant to streamline the review and approval process for novel, low-risk devices but was so cumbersome (and nonsensically requires the petitioner to first file a 510(k) then for FDA to respond with a “Not Substantially Equivalent” (i.e. no predicate) letter before it can be refiled as a straight de novo) and time consuming that it was hardly ever used.

The FDA Safety and Innovation Act of 2012 brought a significant change by creating the direct de novo pathway which does not require an initial 510(k) filing. Instead an applicant can directly apply for their device to be considered a Class I or Class II device (with general or general and special controls).

Why SNWV's pivot from PMA to de novo? FDA has some discretion in the criteria and information that they use and how they apply that in determining whether a particular device should be cleared for sale. While this creates some ambiguity in terms of their decision-making process, there is no question that an acceptable benefit-risk profile is of paramount importance. The following document sheds some light on how FDA applies the risk-benefit tradeoff for the PMA pathway and for the de novo pathway.

Per FDA's, “Guidance for Industry and Food and Drug Administration Staff - Factors to Consider When Making Benefit-Risk Determinations in Medical Device Premarket Approvals and De Novo Classifications”, FDA determines whether PMA applications provide a “reasonable assurance of safety and effectiveness” by “weighing any probable benefit to health from the use of the device against any probable risk of injury or illness from such use,” among other relevant factors. To aid in this process, PMA applicants submit valid scientific evidence, including one or more clinical investigations where appropriate, which FDA reviews to determine whether “the device will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in the labeling of the device.” FDA staff review the data submitted as part of the PMA application and determine – based on a number of factors – if the data support the claims made by the sponsor concerning clinically significant results from the device, i.e., intended use and indications for use, and if the data analysis demonstrates that the probable benefits of the device outweigh its probable risks.
A balanced consideration of probable benefits and probable risks is an essential part of FDA's determination that there are reasonable assurances of safety and effectiveness.

Regarding the de novo pathway it goes on to say, *Because devices classified under this pathway (de novo devices) are low to moderate risk devices, they may not need to confer as substantial a benefit to patients in order to have a favorable benefit-risk profile. Devices granted marketing authority under de novo petitions should be sufficiently understood to explain all the risks and benefits of the device such that all risks can be appropriately mitigated through the application of general and/or special controls to provide reasonable assurance of safety and effectiveness.*

If the primary endpoint (statistically superior difference in 100% wound closure at 12 weeks) had been met using the combined (pivotal plus supplemental clinical trials) study data, SNWV would have filed a PMA application. But the primary endpoint was not met. While the clinical data shows an efficacy signal, including significance on 100% wound closure at 20 weeks and, with certain sub-groups (such as high BMI patients), at 12 weeks, we think SNWV concluded (based on advice from MCRA, and potentially from feedback from FDA) that the benefit (i.e. efficacy), as interpreted by FDA under the PMA pathway, was not strong enough to support PMA approval. Or at least, not strong enough for approval without first going through a panel review – a process which would be drawn out and which could still result in a not approvable response.

By pursuing the de novo pathway, SNWV shifts more of the emphasis to the strong safety profile of dermaPACE, essentially lowering the approval hurdle given that, per FDA’s guidance above, Class II devices “may not need to confer as substantial a benefit to patients in order to have a favorable benefit-risk profile”.

As a reminder safety has been a non-issue. There was not a statistically significant difference in safety between the dermaPACE and control arms in the pivotal or supplemental study or when the data was combined with Bayesian analysis. In the combined data, 73.2% of dermaPACE subjects reported adverse events compared to the control's 68.9% (p=0.338). 55.8% of subjects saw treatment-emergent adverse events versus the control's 51.2% (p=0.444). Differences were not statistically significant.

We think the de novo pathway makes sense given dermaPACE's strong safety profile and the fact that FDA had previously communicated to SNWV that they will consider the totality of the efficacy data. As we have outlined in our discussion of the combined studies’ results, there is an obvious efficacy signal. Another point in dermaPACE's favor, which relates to safety and lack of adverse events, is the non-invasive nature of the device – which would provide an alternative to other relatively invasive DFU therapies including negative pressure and skin substitutes.

Other considerations of de novo pathway:

- **Review Time:** For PMA's FDA's stated goal is to review and make an approval decision within 180 days. For direct de novo applications their stated goal is to make a determination within 120 days. In reality, however, FDA’s turnaround time for both pathways is typically much longer than their cited respective timeline goals. PMA applications over the last few years have, on average, taken 15 – 18 months for the FDA to make a decision. And while one of the potential benefits that FDA has cited for the creation of the de novo pathway was reduced review and approval times, according to a study by Hogan Lovells U.S. LLP, average review time for de novo applications in 2014 and 2015 was almost 400 days – while better than average PMA review time, this suggests SNWV may not hear a final decision until late Summer 2017 or later.

- **Competitive considerations:** assuming dermaPACE is cleared for sale as a Class II device, it potentially opens the door for competitors to cite it as a predicate device under a 501(k) clearance pathway. However, in reality it may not be that straightforward given the proprietary nature of SNWV's technology, the relative robustness of the randomized clinical trial design and supporting clinical data (notwithstanding the missed primary endpoint) and the special controls (required for a Class II submission) which may provide enough differentiation to thwart any competitors' attempts to claim “substantial equivalence” to dermaPACE. In addition, if SNWV were to successfully expand the label (for example to include other types of chronic wounds), precedent has suggested that FDA may disallow the 510(k) pathway for any competitors (that

1 http://www.meddeviceonline.com/doc/the-de-novo-classification-process-a-work-in-progress-001
were successful in citing dermaPACE as a predicate for chronic DFU) seeking the same indication to follow de novo.

➤ Wasn’t an option until 2012: SNWV’s pivotal dermaPACE study commenced in 2007 and the third and final module of the PMA filing was made in July 2011. The direct de novo pathway was not an option until July 2012. It’s possible that SNWV would have initially chosen the direct de novo route had it been available.

➤ Switching from PMA to de novo: given the uniqueness of the situation, we do not know if the late-hour switch from PMA to de novo presents the potential for any distinct administrative or regulatory issues with FDA. We assume, however, that MCRA has already addressed anything that may relate to this and has enough comfort of the viability of switching to the de novo pathway.

➤ Lower regulatory burden, cost: the de novo route may provide some relief to the regulatory burden as compared to PMA. While panel review was a real possibility with PMA, there is less likelihood that FDA will convene a panel with de novo. De novo submissions do not require the applicant to pay a user fee and typically will not require post-marketing studies (although the latter can be on a case-by-case basis). And, perhaps, most significant as it relates to regulatory burden is that if SNWV seeks in the future to expand the dermaPACE label, de novo clearance is much more streamlined than if PMA was pursued.

**Trial Data Refresher**

**U.S. dermaPACE Update:** Combined data hit 100% closure @ 20, 24 weeks but supplemental trial missed on these measures. Promising sub-group and secondary data…

Additional supplemental clinical study and combined data (i.e. when the pivotal and supplemental data were combined using FDA-agreed Bayesian analysis) were announced in March 2016. As a reminder, 100% wound closure at the 12-week follow-up was the primary endpoint in both the pivotal and supplemental studies. Both studies failed to meet this. A subsequent meeting with FDA revealed that the agency was open to considering the totality of the data to support an efficacy claim in a future regulatory filing. As the pivotal study had shown statistical significance of 100% wound closure at 20 weeks, SNWV analyzed the combined data using that timepoint, as well as at 24 weeks, as a proxy for the primary endpoint.

In October 2015 the company announced that while the supplemental study did not hit statistical significance of 100% wound closure at 20 weeks, the combined data did. We noted that that was a highly promising development as had the combined data not shown statistically superior efficacy of dermaPACE over sham at the 20-week mark, that it was our opinion that the device would have had little to no chance of eventually gaining FDA approval/clearance. And, importantly, safety has not been an issue in either of the studies or when the studies were analyzed together.

On March 24th SNWV announced additional clinical data, through 24 weeks, related to both 100% wound closure as well as secondary endpoints and other potentially relevant results. Particular points of interest in the most recent announcement include:

**100% wound closure:**
- on combined analysis (i.e. data from both studies analyzed together) dermaPACE showed statistically significant superior efficacy over sham control in 100% wound closure at 24 weeks (in addition to the prior data which showed the same at 20 weeks)
  - 20 weeks: 35.5% dermaPACE vs. 24.4% control, p=0.027
  - 24 weeks: 37.8% dermaPACE vs. 26.2% control, p=0.023
  - In addition, management noted that there was a trend of superior efficacy of dermaPACE in wound closure beginning around week 14
  - 12 weeks: while more dermaPACE patients achieved 100% wound closure at 12 weeks as compared to sham control (22.7% vs. 18.3%), the difference was not statistically significant (p=0.32)
- supplemental study: dermaPACE was not statistically different than that of sham control in 100% wound closure at 20 weeks (p=0.339) or 24 weeks (35.4% vs 26.2%, p=0.254)

**Secondary endpoints and other relevant analysis:**
- **Rate of healing**: combined data showed approximately 25% of dermaPACE patients reached wound closure by week 12 (i.e. final follow-up of primary endpoint). The same percentage (25%) in the sham control group did not reach wound closure until day 112 (i.e. end of week 16).
  - Combined data showed a statistically significant difference \((p=0.0346)\) through 24 weeks favoring dermaPACE in the time to wound closure.

- **Wound area reduction**: combined data showed statistically significant reduction in wound area favoring dermaPACE. The average wound area reduction in dermaPACE subjects was 1.92cm\(^2\) compared to 0.16cm\(^2\) in the control group at 24 weeks \((p=0.047)\).
  - Combined data showed a statistically significant difference in wound area reduction favoring dermaPACE from the week-six follow up through the end of the study.
  - Achievement of 50% wound area reduction also favored dermaPACE, although this just missed statistical significance at both 12 and 24 weeks.
    - 66.9% of dermaPACE patients achieved at least a 50% decrease in wound size at 12 weeks compared to 60.4% in the control group \((p=0.0554)\).
    - 70.4% of dermaPACE patients achieved at least a 50% decrease in wound size at 24 weeks compared to 61.6% in the control group \((p=0.0899)\).

- **Wound expansion**: combined data showed statistically significant superior efficacy of dermaPACE compared to control in prevention of wound expansion. dermaPACE demonstrated superior results in the prevention of wound expansion \((\geq 10\% \text{ increase in wound size})\) over the course of the study at 12 weeks \((18.0\% \text{ versus } 31.1\%; p=0.005\text{, respectively})\). While this trend continued through 24 weeks, the difference did not remain statistically significant.

- **Amputations**: at 24 weeks, the limb amputation rate of the target ulcer was 2.3% for dermaPACE versus 3.0% in the control group. While the difference was not statistically different \((p=0.745)\), the trend did favor dermaPACE and, given that amputations are relatively rare, the study would have needed to be much larger to demonstrate statistical difference in amputations.

- **Recurrence rates**: combined data showed that at 24 weeks 92.3% of dermaPACE subjects who demonstrated wound closure did not have a recurrence of DFU versus 88.4% in the control group. Again, while not statistically different \((p-value=0.490)\), the trend in recurrence rate did favor dermaPACE. But, perhaps more important is that this 92.3% non-recurrence rate (which is similar to the 95.5% non-recurrence rate of the pivotal dermaPACE study) compares very favorably to recurrence rates in clinical studies as high as 19% and 40% of Dermagraft and Apligraf, respectively. These are (relatively invasive and costly) skin substitutes used to treat DFU and potential competitors to dermaPACE.

**Demographic sub-group analysis**: a deeper dive was done to flesh out any differences-of-interest in results based on patient demographics. This could be relevant to design of potential follow-up studies.

- **Height**: combined data showed statistically significant superior efficacy of dermaPACE compared to sham control \((30.0\% \text{ vs } 14.1\%)\) in 100% wound closure at 12 weeks with patients measuring 70 inches and taller.

- **Age, BMI, height, sex**: while the combined data did show statistically superior efficacy of dermaPACE over sham control at 24 weeks, there were sub-populations in which efficacy of dermaPACE was even more pronounced. Patients younger than 65 years, body mass index (BMI) less than 32, height greater than or equal to 70 inches, and male subjects all had success rates statistically significantly higher than the control group \((p < 0.050)\).

**Safety remains a non-issue**: there was not a statistically significant difference in safety between the dermaPACE and control arms in the pivotal or supplemental study or when the data was combined with Bayesian analysis. In the combined data, 73.2% of dermaPACE subjects reported adverse events compared to the control's 68.9% \((p=0.338)\). 55.8% of subjects saw treatment-emergent adverse events versus the control's 51.2% \((p=0.444)\). Differences were not statistically significant.

**Assuming FDA does consider the totality of the data, there is reason to be hopeful that there is a pathway towards eventual U.S. marketing approval...**

- While the supplemental study did not demonstrate an efficacy difference of dermaPACE versus sham control (i.e. standard of care) on the 100% wound closure measure for the entire trial population, it did show a statistically superior difference on this measure in those patients with a BMI of less than 32 (i.e. less obese patients).
- the pivotal study as well as the combined data showed statistically superior efficacy of dermaPACE compared to sham control at both 20 and 24 weeks.

- combined data showed statistically significant superior efficacy of dermaPACE compared to sham control (30.0% vs 14.1%) in 100% wound closure at 12 weeks with patients measuring 70 inches and taller.

- there were sub-populations in which efficacy of dermaPACE was even more pronounced at 24 weeks. Patients younger than 65 years, body mass index (BMI) less than 32, height greater than or equal to 70 inches, and male subjects all had success rates statistically significantly higher than the control group (p = ≤ 0.050).

- there was also statistically significant differences or at least trends favoring dermaPACE over control in rates of healing, wound area reduction, prevention of wound expansion, amputations and recurrence rates. Recurrence rates of both dermaPACE studies also compare favorably to clinical studies of Dermagraft and Apligraf.

- safety has consistently been a non-issue with dermaPACE. All other leading DFU therapies (skin substitutes, gels and VAC) are more invasive and susceptible to greater safety risks. As FDA must weigh risk and reward when considering approval of a novel therapy, dermaPACE's relatively low risk profile could work to lower its respective efficacy hurdle. By pursuing the de novo pathway, SNWV shifts more of the emphasis to the strong safety profile of dermaPACE, essentially lowering the approval hurdle given that, per FDA's guidance, Class II devices "may not need to confer as substantial a benefit to patients in order to have a favorable benefit-risk profile."

- one-size may not have to fit all with FDA. While 100% wound closure at 12 weeks has been the recent historical standard by which FDA has judged efficacy of DFU therapies, the fact that the agency continues to entertain the possibility of a pathway of approval for dermaPACE may mean they are open to other considerations. Given the strong safety profile of dermaPACE and less invasive nature as compared to other DFU therapies, coupled with efficacy signals in wound area reduction, rate of healing and lower recurrence, we think the de novo pathway makes sense.
HISTORICAL ZACKS RECOMMENDATIONS

SANUWAVE HEALTH (MW) Price ($)
DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, Brian Marckx, CFA, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article. Zacks SCR has received compensation from the issuer directly or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer’s business. SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.